This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (36)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Practical and Ethical Issues

Allen D. Roses, MD

Arch Neurol. 1997;54(10):1226-1229.

Abstract
The dissection of the heterogeneous genetics of the Alzheimer diseases (ADs) is currently more advanced than in any other common disease. Not only are 3 uncommon autosomal dominant mutation loci identified, but universally inherited susceptibility polymorphisms associated with risk and age of onset distributions for familial and "sporadic" AD are also confirmed. The utility of testing for mutations of the amyloid precursor protein and the presenilin 1 and presenilin 2 genes conforms to strategies in common use for rare mutations. The selection of patients with very early-onset AD, especially those with family histories of the disease, will increase the possibility of diagnosis. All testing should be performed using recommended counseling procedures. Apolipoprotein E (ApoE) susceptibility polymorphisms are genetic risk factors but do not allow prediction of the age of onset of AD for cognitively normal individuals. Recent large, collaborative studies have found that when ApoE genotyping is used sequentially in diagnosis following criteria-based evaluations, the specificity of early diagnosis is significantly increased. For patients clinically diagnosed with AD who carried an ApoE 4 allele, the positive predictive value was 94% and 97% in 2 multicenter collaborative series. The utility of ApoE genotyping is reviewed and recommendations for early use in diagnosis are explained. There are ethical, social, actuarial, and legal problems currently associated with genetic testing and these concerns are also discussed.

Author Affiliations
From the Center for Human Genetics, Duke University Medical Center, Durham, NC. Duke University Medical Center has been awarded a patent on the application of apolipoprotein E genotyping to the diagnosis of Alzheimer disease. This patent has been licensed exclusively by Athena Neurosciences, Worcester, Mass. Dr Roses is now with Glaxo-Wellcome Inc, Research Triangle Park, NC.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Genetic Risk Assessment for Adult Children of People With Alzheimer's Disease: The Risk Evaluation and Education for Alzheimer's Disease (REVEAL) Study
Roberts et al.
J Geriatr Psychiatry Neurol 2005;18:250-255.
ABSTRACT  

Genetic susceptibility for Alzheimer's disease: Why did adult offspring seek testing?
Hurley et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2005;20:374-381.
ABSTRACT  

The Utility of Apolipoprotein E Genotyping in the Diagnosis of Alzheimer Disease in a Community-Based Case Series
Tsuang et al.
Arch Neurol 1999;56:1489-1495.
ABSTRACT | FULL TEXT  

Toward an Understanding of Frailty
Hamerman
ANN INTERN MED 1999;130:945-950.
FULL TEXT  

The Aging Brain: Limitations in Our Knowledge and Future Approaches
Katzman
Arch Neurol 1997;54:1201-1205.
ABSTRACT